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Abstract
Myopia is a significant worldwide public health concern, and its prevalence is 
drastically increasing in recent years. It was once viewed as a benign refractive error, 
but is now one of the leading causes of blindness and is associated with numerous 
ocular diseases, which makes it crucial to develop viable treatment options to ade-
quately correct the refractive error and to halt the disease progression. The treatment 
of myopia can be classified into three groups: optical, pharmacological, and surgical 
management, which are aimed at adjusting to the refractive error and reducing the 
axial elongation. The conventional treatment modalities for myopia, such as single 
vision glasses, correct the refractive error and improve visual quality of life, but do not 
affect myopia progression or axial elongation. The newer and various myopic inter-
ventions including spectacle corrections, contact lens corrections, pharmacological 
treatments and surgical corrections, hold great potential for adequate disease control 
to improve the quality of life, reduce myopia burden, and preserve the ocular health.
Keywords: myopia, refractive error, axial elongation, single vision lenses,  
multifocal lenses, rigid gas permeable contact lenses, soft bifocal contact lens, 
orthokeratology, atropine, pirenzepine, anti-hypoxic drugs
1. Introduction
Myopia is a refractive condition of the eye that has globally affected 1.89 billion 
people worldwide, and projected to affect 2.56 billion people by the year 2020 [1]. 
Over the past few decades, the prevalence of myopia in Asia has increased dramati-
cally affecting as much as 80–90% of the pediatric Asian population, and 25–50% 
of the American and European population [2].
Refractive development in early ocular growth is an intricate and continuous 
process. At birth, there is a high prevalence of large refractive errors in newborn 
infants due to mismatch between the axial length and the focal length of its optics 
[3–5]. As the newborn matures, the eye develops in size and refracting power in a 
rapid fashion to attain an ideal refractive state in early childhood. This physiological 
process is known as emmetropization [5–7]. Coordination between axial length and 
optical components will allow for the images of distal objects to focus on the retina, 
rather than in front or behind it [5]. Interruption of this homeostatic process of 
ocular growth results in the development of refractive error. The disorder manifests 
in early childhood and progresses at an average of 0.5D every year until stabilizing 
during adolescence [8–10].
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It was once considered a mere refractive error, but myopia is now often associ-
ated with a multitude of ocular diseases such as retinal detachment, glaucoma, 
cataract and chorioretinal abnormalities [11]. Therefore, in recent years, the focus 
of myopia research has been on halting the progression to decrease the risk of 
associated future ocular diseases.
This chapter focuses on the mechanics of the various treatment methods includ-
ing optical, pharmacological and surgical strategies, for precise control of myopia. 
The goal of such treatment methods is to reduce both personal and societal burden, 
as well as prevent disease progression such as worsening refractions, axial length 
and overall ocular health.
2. Treatment of myopia
2.1 Optical management
2.1.1 Spectacle correction
While potential optical strategies are investigated for adequate myopia control, 
the visual outcomes of Single Vision Lenses (SVLs) are used as control for efficacy 
comparison. Single vision lenses (SVLs) have universally been utilized by oph-
thalmologists and optometrists for correction of refractive error. With periodic 
monitoring, the spectacle prescription is often adjusted to correct the increasing 
refractive error. The growth of the eye is regulated by visual signals, which are 
manipulated and controlled by the power of the spectacle lens [5]. By regulating 
the refractive error of the cornea and the axial length of the eye, SVLs emulate the 
eye’s innate process of emmetropization by allowing the eye to focus the rays on the 
retina [5, 12].
While visual outcomes are improved, SVLs do not interrupt the myopia 
progression or axial length elongation. Though clinically insignificant, evidence 
from animal studies suggest compensatory eye growth in spectacle induced 
emmetropization [13, 14]. Since SVLs alter the refractive error but does not reduce 
progression or axial elongation, studies have investigated on alternate optical cor-
rection methods, such as under-correction of refractive error.
Animal studies have postulated that under-correction of the refractive error 
reduces the mean change in refractive error, in comparison to fully-corrected SVLs. 
Hence, some clinicians advocate for under-corrected SVLs in an attempt to reduce 
the axial growth and prevent further myopia progression. It is theorized that mod-
est under-correction of SVLs by 0.5–0.75D reduces the accommodative stimulus 
and consequently the blur drive for near work accommodation [15, 16]. However, 
studies have demonstrated contradicting results.
The pilot randomized study performed by Chung et al. compared the effects of 
under correction versus full correction on Hong Kong Chinese children. The study 
demonstrated that myopia progression was slightly greater in patients with under-
correction in comparison to full correction, with 0.5 and 0.35D, respectively [17]. 
Similar results were obtained by study conducted by Adler et al., which showed 
0.66 versus 0.55D for patients with under-correction and full correction, respec-
tively [18]. Both studies concluded that myopic defocus through under-correction 
slightly increased the rate of myopia progression. While SVLs attend to the refrac-
tive error and vision complaints of the child, it does not have a protective role on the 
health and growth of the eye.
As an alternative to SVLs, multifocal lenses have gained popularity for use in 
slowing or halting the progression of myopia and axial elongation of the eye. It 
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is believed that these lenses decrease the rate of myopia progression by reducing 
accommodation effort and hyperopic defocus. A relatively newer version of the 
multifocal lenses is Progressive Addition Lenses (PALs). The Correction of Myopia 
Evaluation Trial (COMET) study is the largest double randomized, double masked 
clinical trial that evaluates the effect of PALs versus SVLs on the progression of 
myopia in children. Although clinically insignificant, the study revealed decreased 
mean increase of myopia in children treated with PALs, compared to children with 
SVLs [13, 19].
A similar study conducted by Hasebe et al. investigated the effects of PALs 
versus SVLs on slowing the progression of myopia using a crossover design, which 
switches the spectacle type at the half of the study. At the end of this 3-year study 
period, progression was less in the group wearing PALs first than the group with 
SVLs first. The study concludes that early intervention with PALs is more effective 
that SVLs in controlling myopia, slowing progression and halting axial elongation 
of the eye [20]. Several other statistically significant, but clinically insignificant, 
studies have explored the use of PALs compared to SVLs for slowing the progression 
of myopia [21–23]. With more large population and long duration studies, the stud-
ies can achieve statistical and clinical significance in preventing myopia progression 
and axial elongation.
Myovision lenses appear similar to SVLs, but they are a newer design of spec-
tacles that correct central and side vision that are experimented on many myopic 
Asian pediatric populations. The mechanism of these spectacles is to reduce the 
peripheral hyperopia and prevent myopia progression. These lenses resemble SVLs 
in appearance, are comfortable to wear and easy to adapt to the young population 
[24]. Similar studies with MyoVision lenses on Japanese children, which reveal an 
insignificant difference between the effect of MyoVision lenses and SVL wearers on 
spherical equivalent refraction and axial elongation of the eye [25].
At this early stage of exploration, the efficacy of MyoVision lenses are not yet 
fully understood or proven. With additional studies that can reduce peripheral 
hyperopic defocus more effectively, there is more potential for reduction of myopia 
progression and axial elongation.
2.1.2 Contact lens correction
Majority of the myopic population advocate for contact lenses are from the adult 
population, as it produces cosmetic benefits in addition to functional improvement 
of the vision and their quality of life. However, contact lenses, such as rigid gas 
permeable contact lens, have also been utilized in the pediatric population to retard 
myopia progression and decrease axial elongation.
Rigid gas permeable contact lenses have been shown to retard myopia progres-
sion in studies such as, The Contact Lens and Myopia Progression (CLAMP), which 
explored the progression of myopia in rigid gas permeable contact lens wearers 
versus soft lens controls. The CLAMP study reported that in 2 years the myopia 
progression was less in rigid gas permeable wearers (−1.56 ± 0.95D) than in soft 
contact lens wearers (−2.19 ± 0.89D) [11, 26]. Numerous other studies have demon-
strated that the provisional decrease in myopia progression in rigid gas permeable 
contact lens wearers in comparison to other treatment groups, was a consequence of 
flattening of the cornea, and not the axial length of the eye [26–28].
Soft bifocal contact lens has demonstrated slowing of myopia progression by 
reducing the accommodation effort and halting axial elongation [29]. These lenses 
are designed with power for distance in the center and additional power in the 
periphery, or inversely, which corrects central myopia and reduces relative periph-
eral hyperopia. A study conducted by Walline et al. compared the effects of soft 
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multifocal contact lenses with single vision lenses, and reported that the average 
myopic progression at 2 years was 0.41 ± 0.03D for the single-vision contact lens 
wearers and 0.29 ± 0.03D for the soft multifocal contact lens wearers [29]. While 
the study produced statistically significant results, it was clinically insignificant.
Using a contralateral eye study design, Anstice et al. demonstrated that the eye 
wearing soft bifocal contact lens have a slower axial elongation in comparison to the 
eye wearing soft single vision contact lens. However, this was not clinically signifi-
cant [30].
There is much potential for soft bifocal contact lenses to reduce myopic progres-
sion and axial elongation, which can be achieved with future large-scale studies that 
explore the mechanism of myopic control through reduced accommodation effort 
and studies that compare the effectiveness of soft bifocal contact lens with other 
modes of optical control of myopia.
Orthokeratology is a technique used in the reduction of myopia by flattening the 
cornea by the rigid orthokeratology contact lenses. The pattern of lens wear in this 
correction technique allows for the correction of myopia for short periods of time. 
The lenses are worn overnight to temporarily alter the corneal shape by corneal 
thinning, are removed during the day when the visual acuity would be improved 
temporarily [31]. The Berkeley Orthokeratology study demonstrated a significantly 
greater reduction of myopia in orthokeratology contact lens wearers, in comparison 
to a control group. However, the study was not clinically significant [9, 32].
The Longitudinal Orthokeratology Research in Children study was explored 
the effects of Orthokeratology contact lenses worn for 2 years on children in Hong 
Kong. At the study end, the there was a significant difference in the axial length 
between the lens wearers and the control group, 0.29 and 0.54 mm, respectively. 
The study was not clinically significant, represents the need for large scale studies to 
achieve clinical and statistical significance [31, 33].
With additional studies that can reduce peripheral hyperopic defocus more 
effectively, there is more potential for reduction of myopia progression and axial 
elongation.
2.2 Pharmacological management
2.2.1 Atropine
Atropine is a non-selective muscarinic antagonist that has been the most effec-
tive in slowing the progression of myopia. One theory for the mechanism of atro-
pine is the role of scleral remodeling in myopia and axial elongation. The expression 
of the muscarinic receptors (mAChRs) results in the proliferation of fibroblasts in 
the scleral collagenous matrix, which promotes scleral remodeling and ultimately 
axial elongation [34]. Some axial elongation induced morphological scleral changes 
include lamellar arrangement of collagen fibers in myopic eyes rather than the tight 
interwoven collagen fibers in emmetropic eyes, the reduction in fibril diameter, a 
dispersed range of fibril diameters, and an increased number of abnormal fibrils 
represent are representations [35, 36]. It is theorized that atropine receptor block-
age interrupts scleral fibroblast proliferation and consequential axial elongation 
of the eye. Although the mechanism of atropine remains obscure, there are several 
working theories on the action and effect of this drug on myopia progression and 
axial elongation.
The Atropine in the Treatment of Myopia (ATOM) study was conducted from 
1999 to 2004, which explored the effect of atropine 1% instilled nightly in children 
in Singapore for 2 years. The study contained two phases: a 2-year treatment phase 
and a 1-year washout phase. At the end of the 2-year study period, there was a 
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77% reduction in myopia progression with an unaltered axial length, compared to 
the control [37, 38]. The study was originally conducted in Asia but was adopted 
by other countries due to its encouraging results [39–43]. Following a successful 
2-year treatment phase, the patients displayed rebound phenomenon in the 1-year 
washout phase. During this phase, there was an increase in both refractive error and 
axial length [37, 38]. The instillation of topical atropine was generally tolerated with 
some short- and long-term side effects. Short-term side effects are red eyes, photo-
phobia, dilatation, increased intraocular pressure and glaucoma, and long-term side 
effects include retinal vascular diseases and cataract formation [37, 38]. The ATOM 
study was proved highly effective in reducing the rate of axial elongation and 
myopia progression, but was associated with such expected side effects.
Following the ATOM1 study was a 5-year clinical trial, which investigates low-
dose atropine on reducing the progression of myopia, and subsequently decreasing 
the side effects. ATOM2 participants were randomly assigned to receive 0.5, 0.1 
or 0.01% concentration of atropine for 24 months, followed by a 1-year washout 
phase. The results of ATOM2 study reveals that 0.01% is a viable concentration for 
reducing myopia progression and increasing the safety profile [44, 45].
While both ATOM and ATOM2 studies display efficacy in reducing myopia 
progression, both studies reveal a dose-dependent rebound phenomenon during 
the washout period. More recently, The Low-Concentration Atropine for Myopia 
Progression (LAMP) study was conducted to evaluate the efficacy and safety of 
low concentrations of atropine eye drops including 0.05, 0.025 and 0.01% com-
pared to a placebo. The LAMP study revealed that all three low concentrations of 
atropine reduce myopia without a discernable adverse effect on the visual quality 
of life, and 0.05% was the most effective in controlling the spherical equivalent 
progression and the axial elongation over the 1-year study period [46]. Numerous 
studies have compared the effect of atropine to other optical strategies, such as 
single vision lenses, multifocal lenses, rigid gas permeable contact lenses, and 
orthokeratology [47–49].
Combination studies have explored the effects of atropine and an optical cor-
rection for greater myopia control. Shih et al. demonstrated that multifocal lens 
wearers treated with 0.5% atropine have a greater reduction of axial elongation and 
myopia progression, compared to placebo group [50]. Atropine eye drops for the 
treatment of myopia control has gained wide popularity in Asian countries, and 
more recently it has been adopted by the Western countries as well. With further 
investigation and modification to the treatment regimen that evades rebound phe-
nomenon, atropine has the potential to be the conventional treatment of myopia.
2.2.2 Pirenzepine
Pirenzepine is a selective M1 muscarinic receptor antagonist with a similar 
mechanism as atropine in halting myopia progression and axial elongation. A 
study conducted by Siatkowski et al. developed a 2% pirenzepine gel that displayed 
great efficacy in reduction of refractive error compared to the placebo group. 
Additionally, the average axial length increase at 1 year was 0.19 mm for patients in 
pirenzepine treatment group compared to 0.23 mm for those in the placebo group. 
While the results are statistically significant, they are clinically insignificant [51]. 
The adverse events in patients treated with pirenzepine were mild to moderately 
severe and included mydriasis, erythema of eyelids and ocular itching [9, 51, 52]. 
Overall, the study displayed good safety and efficacy for use in myopia control. 
Future studies are warranted to compare the efficacy and safety of pirenzepine 
and atropine in slowing the progression of myopia and axial elongation. Atropine 
eye drops for the treatment of myopia control has gained wide popularity in Asian 
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countries, and more recently it has been adopted by the Western countries as well. 
With further investigation and modification to the treatment regimen that evades 
rebound phenomenon, atropine has the potential to be the conventional treatment 
of myopia.
2.2.3 Anti-hypoxic drugs
Anti-hypoxic drugs such as salidroside and formononetin have shown anti-
hypoxic effects to treat scleral hypoxia in myopia [53, 54]. Scleral hypoxia, which 
is induced by Hypoxia-Inducible Factor-1α (HIF-1), triggers a signaling cascade 
for myofibroblast trans-differentiation leading to scleral extracellular collagenous 
matrix remodeling in progressing myopia [55]. Formononetin is known decrease 
HIF-1α, vascular endothelial growth factor (VEGF) and prolyl hydroxylase 
domain-2 (PHD-2), which are protective in hypoxia-induced retinal neovascular-
ization [54]. Salidroside is protective against for hypoxia-induced cardiac apoptosis 
and pulmonary hypertension [56, 57].
In animal models with experimentally induced myopia, anti-hypoxic drugs 
down-regulated HIF-1α expression and the phosphorylation levels of eIF2α and 
mTOR to inhibit the development of form deprivation myopia, without affecting 
the normal ocular growth in guinea pigs [55]. Due to encouraging results in animal 
models, the use of anti-hypoxic drugs shows great potential for treatment of myopia 
in human eyes.
2.3 Surgical management
Surgeons have recently advocated for surgical intervention to halt the progres-
sion of myopia, axial elongation and weakening of the posterior sclera. Macular 
buckle surgery or posterior reinforcement (PSR) surgery is proven to be effective 
in reinforcing the weakened posterior sclera. A scleral buckle is used to apply direct 
mechanical force onto the posterior pole, which slows the axial elongation. Shen 
et al. documented significantly higher Best-Corrected Visual Acuity (BCVA) and 
lower refractive error in the group who underwent macular buckle surgery com-
pared to the control group [58]. Additionally, patients who underwent PSR surgery 
have a shorter mean axial length and lower mean refractive error than the control 
group [59, 60].
Macular buckling surgery has also been used myopic macular hole with retinal 
detachment and posterior staphyloma, which displayed high reattachment rates and 
improved visual acuity [61, 62]. Recent studies have experimented with different 
buckle materials, shapes, techniques and other modifications for the best correc-
tion of myopia and its complications [63–65]. With more advanced techniques and 
modifications, the surgical technique can be utilized as conventional treatment of 
myopia to reduce myopia progression and axial elongation.
3. Conclusion
The global prevalence of myopia is in an increasing trend, with estimates of 
myopia and high myopia affecting nearly 5 billion and 1 billion people, respectively, 
in 2050 [1]. As a major public health concern, it is essential to develop interventions 
that sufficiently delay or stop the progression of myopia. Of the above discussed 
treatments, all have shown to reduce the progression of myopia, but atropine has 
been the most popular and effective in reducing progression and axial elonga-
tion. Despite the expected side effects, its rebound phenomenon and its obscure 
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mechanism, atropine has achieved global popularity. With changes in lifestyle, 
health education, government and other health systems, the importance and 
acceptance of myopia control will significantly diminish number of people affected. 
Additionally, the implementation of a conventional, safe and effective intervention 
for myopia control will significantly reduce the personal, societal and economic 
burden, and decrease the disease progression and the risk of future myopia-induced 
ocular complications.
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